Mangione’s attorneys say they won’t argue psychiatric defense in state murder trial – one day after indicating they would

Mangione’s Attorneys Withdraw Psychiatric Defense in State Murder Trial

Mangione s attorneys say they won t – just one day after expressing intent to use it. On Thursday, the defense team for Luigi Mangione informed the court they would no longer pursue a psychiatric defense in his New York state murder trial. This reversal came shortly after they had hinted at the strategy during a prior hearing, where they suggested the CEO of UnitedHealthcare, Brian Thompson, was killed while the defendant was under an extreme emotional disturbance. The shift in approach was outlined in a court filing, signaling a strategic adjustment ahead of the trial’s start in September.

Defense’s Last-Minute Strategy Change Sparks Debate

The Manhattan District Attorney’s office had expected the psychiatric defense to play a key role in the case, given the circumstances of the December 2024 shooting. Judge Gregory Carro had previously announced plans to unseal documents related to the affirmative defense, which would have allowed Mangione to admit guilt while arguing for reduced liability. However, after the defense’s withdrawal, Carro decided to keep the records sealed, highlighting the tension between the prosecution’s evidence and the defense’s evolving plans.

The psychiatric defense rests on the claim that a defendant’s actions were driven by an extreme emotional disturbance, potentially reducing the charge from murder to manslaughter. If successful, this could have minimized the severity of Mangione’s punishment. Legal analysts noted that the defense’s initial strategy might have been a strong move, especially with the public focus on the case and the evidence linking Mangione to the crime. But the abrupt decision to abandon it has left questions about the defense’s confidence or the strength of their case.

Expert Insights on the Defense’s Rationale

Legal experts speculated on the reasons behind Mangione’s attorneys’ sudden change in direction. One possibility is that the defense felt the evidence against Mangione was too strong to be countered effectively by a psychiatric argument. Another is that the media attention surrounding the case could have made the defense more vulnerable if they had publicly committed to the strategy. By keeping the psychiatric defense under wraps until Thursday, the team may have aimed to control the narrative and avoid premature scrutiny of their claims.

“The defense’s decision to withdraw the psychiatric argument reflects a calculated move,” said Gary Galperin, a former prosecutor. “It’s unclear whether they’re concerned about the evidence or the timing of their strategy.”

In a June 3 hearing, Mangione’s lawyer Karen Friedman Agnifilo explained the defense’s reasoning. According to a transcript unsealed on Thursday, she stated, “If a defendant goes with an EED defense, they’re essentially admitting publicly that they committed this crime.” She emphasized that the high level of media attention in the case could sway jurors, making it essential to keep the defense’s strategy confidential until the final moment.

Background on the Shooting and Legal Proceedings

The fatal shooting of UnitedHealthcare CEO Brian Thompson occurred on December 13, 2024, as he walked toward a Midtown Manhattan hotel for his company’s annual investors’ conference. Mangione, 26, was arrested shortly after the incident and has pleaded not guilty to state murder and weapons charges, as well as federal stalking allegations. His trial in New York state court is scheduled to begin in September, while the federal case remains ongoing.

Mangione’s attorneys had initially argued that the psychiatric defense could be a compelling narrative, given the defendant’s mental state at the time of the shooting. However, the decision to abandon it suggests a shift in focus, possibly toward a more straightforward defense of innocence. The move also raises questions about how the defense will present their case without relying on the mental health argument, which had been a central part of their strategy in the early stages of the trial.